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Implications of applying widely accepted cholesterol
screening and management guidelines to a British adult
population: cross sectional study of cardiovascular disease
and risk factors
Nigel Unwin, Richard Thomson, Ann Marie O’Byrne, Mike Laker, Heather Armstrong
Abstract
Objective: To compare the implications of four widely
used cholesterol screening and treatment guidelines
by applying them to a population in the United
Kingdom.
Design: Guidelines were applied to population based
data from a cross sectional study of cardiovascular
disease and risk factors.
Setting: Newcastle upon Tyne, United Kingdom.
Subjects: General population sample (predominantly
of European origin) of 322 men and 319 women aged
25›64 years.
Main outcome measures: Proportions recommended
for screening and treatment.
Methods: Criteria from the British Hyperlipidaemia
Association, the British Drugs and Therapeutics Bulletin
(which used the Sheffield table), the European
Atherosclerosis Society, and the American national
cholesterol education programme were applied to the
population.
Results: Proportions recommended for treatment
varied appreciably. Based on the British Drugs and
Therapeutics Bulletin guidelines, treatment was
recommended for 5.3% (95% confidence interval
2.9% to 7.7%) of men and 3.3% (1.5% to 5.3%) of
women, while equivalent respective values were 4.6
(2.3 to 6.9) and 2.8 (1.0 to 4.6) for the British
Hyperlipidaemia Association, 23% (18.4% to 27.6%)
and 10.6% (7.3% to 14.0%) for the European
Atherosclerosis Society, and 37.2% (31.9% to 42.5%)
and 22.2% (17.6% to 26.8%) for the national
cholesterol education programme. Only the British
Hyperlipidaemia Association and Drugs and
Therapeutics Bulletin guidelines recommend selective
screening. Applying British Hyperlipidaemia
Association guidelines, from 7.1% (4.3% to 9.9%) of
men in level one to 56.7% (51.3% to 62.1%) of men in
level three, and from 4.4% (2.1% to 6.7%) of women
in level one to 54.4% (48.9% to 59.9%) of women in
level three would have been recommended for
cholesterol screening. Had the Drugs and Therapeutics
Bulletin guidelines been applied, 22.2% (16.5% to
27.9%) of men and 12.2% (8.6% to 15.8%) of women
would have been screened.
Conclusions: Without evidence based guidelines,
there are problems of variation. A consistent
approach needs to be developed and agreed across
the United Kingdom.
Introduction
Considerable attention has been focused recently on
promoting evidence based practice and the potential
of guidelines to inform and support appropriate care
and changes in clinical behaviour.1–3 Guidelines have
been drawn up on the prevention of coronary heart
disease—in particular, on the screening and manage›
ment of patients with lipid disorders. Guidance on the
use of statins, based on the Sheffield table,4 was recently
circulated to all doctors in the United Kingdom.5 There
are important differences in the recommendations of
the major guidelines, however, yet neither these differ›
ences nor the implications for clinical practice have
been studied.
We have applied data from a population based sur›
vey to the different guidelines for a population aged
25›64 years.6 We aimed to describe the potential impli›
cations of differences in commonly available and
widely promoted guidelines produced by the British
Hyperlipidaemia Association,7 the British Drugs and
Therapeutics Bulletin,8 the European Atherosclerosis
Society,9 and the American national cholesterol educa›
tion program.10
Methods
Recruitment and data collection
The data used in this paper are from the Newcastle
heart project—a population based study of coronary
heart disease, diabetes, and associated risk factors in
the general (predominantly of European origin),
Chinese, and South Asian populations of Newcastle
upon Tyne.6 We have used data from the general popu›
lation for this paper. This was a population based sam›
ple from the patient register of the Newcastle Family
Health Services Authority, the list of all individuals in
Newcastle registered with a general practitioner. We
took an age and sex stratified random sample of those
aged 25 to 64 years after removing any Chinese
sounding names (less than 0.5% of the sample).11
Lipid analyses
Subjects were recruited to the study between April
1993 and November 1994. After overnight fasting,
subjects’ height and weight were measured, their body
mass index (kg/m2) was computed, and a fasting blood
sample was taken. Until May 1994 the lipid analyses
were performed on a Cobas Bio centrifugal analyser
(Roche Products Ltd, Welwyn Garden City) and after
this date a DAX analyser was used (Bayer plc,
Basingstoke). Throughout the study period, the labora›
tory participated in an external quality assurance
scheme. This showed no changes in bias (inaccuracy)
for cholesterol or high density lipoprotein cholesterol.
However, the data for triglycerides confirmed that the
DAX data showed a positive bias relative to the Cobas
Bio data and therefore results obtained with the DAX
were adjusted as previously described.12 The low
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density lipoprotein cholesterol concentration was
calculated using the Friedewald formula.7
Cardiovascular data
Subjects had two blood pressure measurements. These
were made by trained observers using a standard mer›
cury sphygmomanometer with an alternate size cuff.13
A 12 lead electrocardiogram was recorded with the
subjects at rest. The findings were coded according to
the Minnesota manual by two independent observers;
a third observer was used where the two disagreed.14
Each subject completed a questionnaire, which
included items on diabetes, hypertension, coronary
heart disease, and stroke (all diagnosed by a doctor);
smoking status; causes of death in any parents or
siblings who had died; and the World Health Organi›
sation questionnaire on intermittent claudication.15 For
women, the questionnaire also inquired about age at
the time of the menopause, and any factors affecting its
onset. Local ethical committee approval was received
for the study and all subjects gave informed consent
before participating.
Applying the guidelines
Space does not permit a detailed description of the
guidelines. Here, we have focused on the people for
whom the guidelines recommend intensive treatment
in the form of rigorous dietary intervention under›
Table 1 Application of guidelines to data*
Population to be screened Population to be treated
British Hyperlipidaemia Association
In order of priority: Presence of coronary heart disease and LDL cholesterol >3.4 mmol/l
Vascular disease Presence of >2 out of: diabetes, hypertension (1)*, current smoker, or obesity and LDL cholesterol
>5.0 mmol/l
Family history (1)* of coronary heart disease Male sex and LDL cholesterol >6.0 mmol/l
Diabetes, hypertension (1)*, current smoker, or
obesity
Female sex, postmenopausal, and LDL cholesterol >6.0 mmol/l
Drugs and Therapeutics Bulletin
Vascular disease, or a family history (1)* of coronary
heart disease; or
Presence of vascular disease and LDL cholesterol >3.4 mmol/l
Particular combination of age, sex, hypertension (1)*,
left ventricular hypertrophy, smoking, and diabetes
from risk table
If no overt vascular disease, decision from table based on combination of age, sex, diabetes, smoking,
hypertension (1)*, left ventricular hypertrophy, and total cholesterol value
European Atherosclerosis Association
All Presence of vascular disease and total cholesterol >5 mmol/l (<6 mmol/l dietary therapy only)
Coronary heart disease risk >20% over 10 years (determined by risk chart according to age, sex, smoking
status, blood pressure, and total cholesterol) and total cholesterol >5 mmol/l (<7 mmol/l dietary therapy
only)
Coronary heart disease risk <20% and total cholesterol >7 mmol/l (<8 mmol/l dietary therapy only)
National cholesterol education programme
All Presence of coronary heart disease and LDL cholesterol >2.6 mmol/l (<3.4 mmol/l dietary therapy only)
LDL cholesterol >3.4 mmol/l (<4.1 mmol/l dietary therapy only) and presence of >2 (3 if HDL cholesterol
>1.6 mmol/l) out of: male, age >45, diabetes, hypertension (2)*, current smoker, postmenopausal female,
family history of coronary heart disease (2)*, HDL cholesterol <0.9mmol/l
LDL cholesterol >4.1 mmol/l (<4.9 mmol/l dietary therapy only) with < 2 risk factors
HDL=high density lipoprotein, LDL=low density lipoprotein.
*See table 2 for definitions of the conditions and risk factors. The studies used two definitions—(1) and (2)—for hypertension and family history of coronary heart
disease.
Table 2 Definition of conditions and risk factors used in applying the data to the guidelines
Condition or risk factor Definition
Included in guideline
British
Hyperlipidaemia
Association
Drugs and
Therapeutics
Bulletin
European
Atherosclerosis
Association
National cholesterol
education
programme
Diabetes Reported doctor diagnosis of diabetes Yes Yes Yes Yes
Hypertension (1) Blood pressure >160 systolic or >95 diastolic or
receiving medication
Yes Yes › ›
Hypertension (2) Blood pressure >140 systolic or >90 diastolic or
receiving medication
› › › Yes
Current smoker Self reported current smoker Yes Yes Yes Yes
Obesity Body mass index >30 kg/m2 Yes › › ›
Vascular disease Reported doctor diagnosis of stroke, angina,
myocardial infarction or heart failure, or positive
on WHO intermittent claudication questionnaire
Yes Yes Yes ›
Coronary heart disease Reported diagnosis of angina or myocardial
infarction
Yes › › Yes
Left ventricular hypertrophy Minnesota codes 3›1 and 3›3 on resting 12 lead
electrocardiogram and hypertension (1)
› Yes › ›
Postmenopausal Self reported cessation of periods Yes Yes
Family history (1) of
coronary heart disease
Death from coronary heart disease in parent or in
sibling aged <60
Yes Yes › ›
Family history (2) of
coronary heart disease
Death from coronary heart disease in father or
male sibling aged <55 or in mother or female
sibling aged <65
› › › Yes
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pinned by professional dietetic advice, with or without
drug treatment. Table 1 summarises how we applied
each of the guidelines to the data. The European
Atherosclerosis Society and national cholesterol edu›
cation program guidelines specify two target levels for
active intervention: one for drug treatment (if a trial of
dietary intervention fails) and the other for intensive
dietary intervention only. Table 2 gives the definitions
of the different conditions and risk factors we used in
applying the guidelines to the study population.
Data analysis
Data were analysed using SPSS software. Results are
presented for 20 year age groups and for all ages (25›64
years) for men and women separately. The results for all
ages were age adjusted to the 1991 England and Wales
male and female populations respectively. Confidence
intervals were calculated using Confidence Interval
Analysis software (BMJ Publishing, London).
Results
Altogether 322 men and 319 women aged 25›64 were
screened, giving a response rate of 67%. Most subjects
were European; 10 men and four women had South
Asian sounding names.11 Table 3 shows the percent›
ages of men and women with the risk factors and con›
ditions used in the analyses. The age adjusted total
cholesterol concentrations were mean (SD) 5.6 (1.1)
mmol/l in men and 5.4 (1.2) in women; the mean high
density lipoprotein cholesterol concentrations were 1.3
(0.4) mmol/l and 1.6 (0.4) respectively; and the mean
low density lipoprotein cholesterol concentrations
were 3.4 (1.1) mmol/l and 3.2 (1.0) respectively.
Table 4 shows the proportions of men and women
who would be screened for cholesterol concentration if
the guidelines of the British Hyperlipidaemia Associ›
ation and the Drugs and Therapeutics Bulletin were
followed. The proportions vary widely from 4.4% in
women of all ages on the first level of the British
Hyperlipidaemia Association guidelines to over 50%
for both men and women on the third level.
Table 5 shows the percentages of men and women
recommended for treatment according to the different
guidelines. In both men and women, the highest
percentages recommended for treatment are associ›
ated with the national cholesterol education program
guidelines. Here 37% of men and 22% of women met
the criteria for active intervention, approximately
evenly divided between those who would be recom›
mended for intensive dietary treatment only and those
who would be recommended for drug treatment if
Table 3 Prevalence of risk factors and coronary heart disease in the study population. Percentages for 25›64 years are directly age standardised to 1991
population of England and Wales
Condition or
risk factor*
Men Women
Age 25›44 (n=128) Age 45›64 (n=194) Age 25›64 (n=322) Age 25›44 (n=112) Age 45›64 (n=207) Age 25›64 (n=319)
No % (95% CI) No % (95% CI) No % (95% CI) No % (95% CI) No % (95% CI) No % (95% CI)
Diabetes 0 8 4.4 (0.5 to 7.3) 8 1.9 (0.7 to 4.0) 3 2.7 (0.6 to 7.6) 5 2.4 (0.7 to 5.6) 8 2.6 (0.9 to 4.3)
Hypertension (1) 11 8.6 (3.7 to 13.5) 51 26.3 (20.1 to 32.5) 62 15.4 (11.5 to 19.3) 2 1.8 (0.2 to 6.3) 36 17.4 (12.2 to 22.6) 38 7.8 (4.9 to 10.7)
Hypertension (2) 21 16.4 (10.0 to 22.8) 84 43.3 (36.3 to 50.3) 105 26.4 (21.6 to 31.2) 3 2.7 (0.5 to 7.6) 58 28.0 (21.9 to 34.1) 61 12.2 (8.6 to 15.8)
Current smoker 48 37.5 (29.1 to 45.9) 61 31.9 (25.3 to 38.5) 109 34.8 (29.6 to 40.0) 39 34.8 (26.0 to 43.6) 53 25.7 (19.7 to 31.7) 92 32.2 (27.1 to 37.3)
Obesity 18 14.1 (8.1 to 20.1) 30 15.5 (10.0 to 21.0) 48 14.5 (10.7 to 18.3) 14 12.5 (6.4 to 18.6) 49 23.8 (18.0 to 29.6) 63 16.3 (12.2 to 20.4)
Vascular disease 2 1.6 (0.2 to 5.5) 31 16.0 (10.4 to 20.6) 33 7.1 (4.3 to 9.9) 1 0.9 (0 to 4.9) 22 10.6 (6.4 to 14.8) 23 4.4 (2.1 to 6.7)
Coronary heart
disease
2 1.6 (0.2 to 5.5) 27 13.9 (9.0 to 18.8) 29 6.1 (3.5 to 8.7) 0 15 7.2 (3.7 to 10.7) 15 2.7 (0.9 to 4.5)
Left ventricular
hypertrophy
4 3.1 (0.8 to 7.8) 7 3.6 (1.6 to 5.8) 11 3.7 (1.6 to 5.8) 0 6 2.9 (0.6 to 5.2) 6 1.3 (0.3 to 3.2)
Postmenopausal — — — 11 10.5 (4.8 to 16.2) 142 70.3 (64.1 to 76.5) 153 33.6 (28.4 to 38.8)
Family history
(1) of
coronary heart
disease
11 8.6 (3.7 to 13.5) 10 5.2 (2.1 to 8.3) 21 7.1 (4.3 to 9.9) 6 5.4 (1.2 to 9.6) 22 10.6 (6.4 to 14.8) 28 7.4 (4.5 to 10.3)
Family history
(2) of
coronary heart
disease
6 4.7 (1.0 to 8.4) 12 6.2 (2.8 to 9.6) 18 5.4 (2.9 to 7.9) 5 4.5 (1.5 to 10.1) 20 9.7 (5.7 to 13.7) 25 6.5 (3.8 to 9.2)
*See table 2 for definitions of the conditions and risk factors.
Table 4 Proportions recommended for cholesterol screening* according to the British Hyperlipidaemia Association and Drugs and Therapeutics Bulletin
guidelines. Percentages for 25›64 years are directly age standardised to 1991 population of England and Wales
Men Women
Age 25›44 (n=128) Age 45›64 (n=194) Age 25›64 (n=322) Age 25›44 (n=112) Age 45›64 (n=207) Age 25›64 (n=319)
No % (95% CI) No % (95% CI) No % (95% CI) No % (95% CI) No % (95% CI) No % (95% CI)
British Hyperlipidaemia Association:
First screening
level
2 1.6 (0.2 to 5.5) 31 16.0 (10.8 to 21.2) 33 7.1 (4.3 to 9.9) 1 0.9 (0.0 to 4.9) 22 10.6 (6.4 to 14.8) 23 4.4 (2.1 to 6.7)
Second
screening level
13 10.2 (5.0 to 15.4) 37 19.1 (13.6 to 24.6) 50 13.2 (9.5 to 16.9) 7 6.3 (1.8 to 10.8) 40 19.3 (13.9 to 24.7) 47 11.1 (7.7 to 14.5)
Third screening
level
69 53.9 (45.3 to 62.5) 123 63.4 (56.6 to 70.2) 192 56.7 (51.3 to 62.1) 55 49.1 (39.8 to 58.4) 128 61.8 (55.2 to 68.4) 183 54.4 (48.9 to 59.9)
Drugs and
Therapeutics
Bulletin
14 10.9 (5.5 to 16.3) 82 42.3 (34.3 to 48.1) 96 22.2 (17.7 to 26.7) 7 6.3 (1.8 to 10.8) 46 22.2 (16.5 to 27.9) 53 12.2 (8.6 to 15.8)
*See table 1 for description of criteria for screening
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dietary measures failed to achieve target levels. The
British Hyperlipidaemia Association guidelines pro›
duced the lowest percentages recommended for treat›
ment (initially intensive dietary measures with drug
treatment if target levels were not reached). These were
4.6% of men and 2.8% of women. Although the
percentages recommended for treatment by the
British Hyperlipidaemia Association and Drugs and
Therapeutics Bulletin were similar, the individuals who
would have been treated often differed (see figure).
Only 2.2% of the population were recommended for
active intervention by both guidelines; an additional
2.1% were recommended by the Drugs and Therapeutics
Bulletin guidelines only and 1.5% by the British Hyper›
lipidaemia Association only.
The figures for the British Hyperlipidaemia Associ›
ation guidelines in table 5 apply to the whole
population—that is, irrespective of whether the
individuals met the criteria for screening by these
guidelines. The figures are lower if they are based only
on those individuals who meet both the screening and
treatment criteria. Thus, the percentage of men and
women who met level one screening criteria and treat›
ment criteria were 2.7% and 1.4% respectively, while
proportions for level two were 3.0% and 1.4% and
those for level three were 3.7% and 2.4%. For the men
and women together, the sensitivity (those defined as
needing treatment who would be screened divided by
all those needing treatment) for screening level three
was 83.3%, and the specificity (those defined as not
needing treatment who would not be screened, divided
by all those not needing treatment) was 45.5%. The cri›
teria for screening and treatment for the Drugs and
Therapeutics Bulletin are such that all those who meet
the criteria for treatment also meet the criteria for
screening, giving, by default, a sensitivity of 100%. The
specificity was 86.6% for men and women together.
Discussion
Strengths and weakness
This paper aimed to describe the differing implications
of commonly available and widely promoted British
(British Hyperlipidaemia Association, Drugs and Thera›
peutics Bulletin), European (European Atherosclerosis
Society), and American (national cholesterol education
program) guidelines for the management of hyper›
lipidaemia. To apply the guidelines to our data we
needed to make several assumptions, sometimes
because of the vagueness of the guidelines and
sometimes because of the limitations of our data.
These included, for example, basing “a strong family
history of premature coronary disease” on reported
death from coronary heart disease in a first degree
relative, as we did not have data on non›fatal events in
relatives.
Three of the four guidelines considered state
explicitly that treatment decisions should be based on
more than one cholesterol measurement. Our data are
based on a single fasting measurement, and, undoubt›
edly, repeat measurements on subjects whose initial
concentrations had been high would have reduced the
numbers recommended for treatment.
In addition, our data are from a population based
survey with a response rate of 67%. This survey may
have underestimated the prevalence of coronary heart
disease and some risk factors. For example, in the
health survey of England, those subjects who
consented to a blood test had a lower mean systolic
blood pressure and lower prevalences of smoking and
coronary heart disease.16 Comparing our data, in 10
year age groups, to those from the health survey of
England suggests that the prevalences of smoking,
obesity, and hypertension (defined as >160/
95 mm Hg or taking antihypertensive treatment) in
men are similar to those for England as a whole in
1993/94.17 The prevalence of hypertension in women
in our sample is around half that found in the health
survey. However, the data we used here are broad and
have enabled us to apply most criteria from the differ›
ent guidelines. Thus, although we cannot claim that
our results reflect accurately the proportion of the
population who require treatment in a clinical context,
we are confident that they do reflect reasonably the
relative differences between the guidelines for screen›
Table 5 Proportions recommended for active lipid lowering treatment by the different guidelines. Percentages for 25›64 years are directly age standardised
to 1991 population of England and Wales
Guidelines
Men Women
Age 25›44 (n=128) Age 45›64 (n=194) Age 25›64 (n=322) Age 25›44 (n=112) Age 45›64 (n=207) Age 25›64 (n=319)
No % (95% CI) No % (95% CI) No % (95% CI) No % (95% CI) No % (95% CI) No % (95% CI)
British
Hyperlipidaemia
Association
2 1.6 (0.1 to 5.5) 18 9.3 (5.2 to 13.4) 20 4.6 (2.3 to 6.9) 1 0.9 (0 to 4.9) 13 6.3 (3.0 to 9.6) 14 2.8 (1.0 to 4.6)
Drugs and
Therapeutics
Bulletin
2 1.6 (0.1 to 5.5) 23 11.9 (7.3 to 16.5) 25 5.3 (2.9 to 7.7) 1 0.9 (0 to 4.9) 16 7.7 (4.1 to 11.3) 17 3.3 (1.3 to 5.3)
European Atherosclerosis Association:
Possible drug
treatment*
1 0.8 (0 to 4.3) 20 10.3 (6.0 to 14.6) 21 5.0 (2.9 to 7.9) 1 0.9 (0 to 4.9) 20 9.7 (6.0 to 14.5) 21 4.5 (2.4 to 7.3)
Intensive dietary
measures only
8 6.3 (2.7 to 11.9) 74 38.1 (31.3 to 45.0) 82 18.0 (13.8 to 22.2) 1 0.9 (0 to 4.9) 31 15.0 (10.1 to 19.8) 32 6.0 (3.6 to 9.2)
All 9 7.0 (3.3 to 12.9) 94 48.5 (41.4 to 55.5) 103 23.0 (18.4 to 27.6) 2 1.8 (0.2 to 6.3) 51 24.6 (18.8 to 30.5) 52 10.6 (7.3 to 14.0)
National cholesterol education program:
Possible drug
treatment*
13 10.2 (4.9 to 15.4) 55 28.4 (22.0 to 34.7) 68 17.5 (13.3 to 21.5) 2 1.8 (0.2 to 6.3) 47 22.7 (17.0 to 28.4) 49 9.5 (6.4 to 13.2)
Intensive dietary
measures only
21 16.4 (10.0 to 22.8) 48 24.7 (18.7 to 30.8) 69 19.7 (15.2 to 23.9) 7 6.3 (2.6 to 12.5) 48 23.2 (17.4 to 28.9) 55 12.7 (9.2 to 16.5)
All 34 26.6 (18.9 to 34.3) 103 53.1 (46.1 to 60.1) 137 37.2 (31.9 to 42.5) 9 8.0 (3.0 to 13.0) 95 45.9 (39.1 to 52.7) 104 22.2 (17.6 to 26.8)
*If intensive dietary measures fail to lower cholesterol to target values.
1.5%
British
Hyperlipidaemia
Association
Drugs  and
Therapeutics
Bulletin
2.2%
2.1%
Proportions of men
and women aged
25›64 years
recommended for
active intervention
by guidelines from
the British
Hyperlipidaemia
Association and the
Drugs and
Therapeutics Bulletin
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ing and treatment, and this was the primary purpose
of this study.
Implications of the findings
There were wide differences between the implications
of some of the guidelines. The highest proportions of
men (37%) and women (22%) came within the
treatment category where the national cholesterol
education program guidelines were applied. The
proportions of men and women recommended for
treatment by the guidelines of the British Hyper›
lipidaemia Association and Drugs and Therapeutics Bul›
letin were similar—men 4.6% compared with 5.3% and
women 2.8% compared with 3.3% respectively.
However, the individuals who would have been treated
differed (figure).Thus, it is not simply that some guide›
lines suggest more aggressive intervention but also that
they advise treatment for different subgroups. It is also
clear that even the most liberal screening criteria
recommended by the British Hyperlipidaemia Associ›
ation (level three in table 1) would not identify all
patients recommended for treatment by those
guidelines.
Balancing considerations of sensitivity and speci›
ficity is a common problem in defining screening
criteria. In this context it is worth noting that the recent
Effective Health Care bulletin on cholesterol and
coronary heart disease comes down firmly against uni›
versal cholesterol screening.18 It also argued cogently
that guidance must be based on the assessment and
management of overall cardiovascular risk and not just
one aspect, such as the cholesterol concentration.
A questionnaire survey of health authorities or
boards in the United Kingdom in 1994 found consid›
erable variation and inconsistency in local criteria for
cholesterol testing and treatment.19 Our local experi›
ence suggests there is much heterogeneity—guidelines
of the British Hyperlipidaemia Association, European
Atherosclerosis Society, and criteria based on the Shef›
field table were used, and, most recently, guidance has
been issued from the Standing Medical Advisory
Committee based on the Sheffield table.5 The implica›
tion is that there are considerable inconsistencies in the
management of hyperlipidaemia within the United
Kingdom. It has been previously observed that locally
produced guidelines for the use of anticoagulants in
atrial fibrillation and widely used hypertension
guidelines also differ greatly in their implications for
numbers treated.20 21
Clear guidance needed
The need for consistent clear guidance on screening
for and management of hyperlipidaemia is ever more
pressing as evidence of the effectiveness of newer but
expensive agents, the statins, accumulates.22–24 Unfortu›
nately, recent guidance issued to all doctors in the
United Kingdom5 falls short of what is required—it
considers only drug management, fails to present the
evidence, and ignores issues of cost effectiveness.25 It
adds to the confusing array of guidelines illustrated in
this paper rather than helping to identify and resolve
the reasons for differences between them.
The major lipid management guidelines published
to date have depended upon consensus development
processes and not on the systematic evidence linked
review of published reports that is now recognised as a
necessary part of the process of developing scientifi›
cally valid guidelines.26 27 Furthermore, none of the
guidelines have addressed the economic and service
consequences of their application as part of their
development process. The need for explicitly derived,
scientifically valid guidelines that include a considera›
tion of costs is clear.
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From trial data to practical knowledge: qualitative study of
how general practitioners have accessed and used
evidence about statin drugs in their management of
hypercholesterolaemia
Karen Fairhurst, Guro Huby
Abstract
Objectives To explore how general practitioners have
accessed and evaluated evidence from trials on the
use of statin lipid lowering drugs and incorporated
this evidence into their practice. To draw out the
practical implications of this study for strategies to
integrate clinical evidence into general medical
practice.
Design Qualitative analysis of semistructured
interviews.
Setting General practices in Lothian.
Subjects 24 general practitioners selected to obtain a
heterogeneous sample.
Results Respondents were generally aware of the
evidence relating to the use of statins in secondary
prevention of coronary heart disease, but they were
less clear about the evidence in primary prevention.
The benefits of statins in secondary prevention were
clearer to them and the social and economic issues
less complex than was the case for use in primary
prevention. Respondents rarely said they appraised
the methods and content of trials, rather they judged
the trustworthiness of the source of trial evidence and
interpreted it within the context of the economic and
social factors which impinge on their practice.
Moreover, trial data become relevant for routine
practice only when underpinned by a consensus on
these issues.
Conclusion Strategies to promote incorporation of
evidence from clinical trials into everyday practice are
likely to be effective if they tap into and build on the
process of local consensus building. Strategies such as
teaching critical appraisal skills and guideline
development may have little effect if they are
separated from this process.
Introduction
Use of evidence from clinical trials to underpin routine
practice is seen as a key part of achieving a cost effec›
tive health service that offers consistent high quality
care.1 2 Evidence based medicine requires doctors to
appraise clinical trials critically to determine the best
way of managing a patient’s clinical problem.3
Evidence based medicine is seen as particularly
problematic in general practice, where clinical prob›
lems are presented in complex social and psychologi›
cal contexts.4 Although support for the principle of
evidence based medicine has been identified among
general practitioners,5 recognised barriers exist to its
implementation. Studies that have explored how
general practitioners access evidence and translate this
into practice suggest that strategies based on critical
appraisal might fail because they are based on unreal›
istic models of how “evidence” is accessed and
evaluated.6–8
We present findings from a study in which general
practitioners reflected on how they access and
incorporate into their practice evidence on manage›
ment of lipid disorders. We chose this subject as data
from recent randomised controlled trials, in particular
from the Scandinavian simvastatin survival study (4S)9
and the West of Scotland coronary prevention study
(WOSCOPS),10 have a high profile and direct relevance
to primary care, and local prescribing data suggest
wide variation between practices in levels of prescrib›
ing of statin drugs. We compared general practitioners’
accounts of their current practice with results from the
two studies. The Scandinavian study produced
evidence of around a 30% reduction in risk of myocar›
dial infarction and death in patients with known
ischaemic heart disease whose total serum cholesterol
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